FindMyKOL
Clinical trialNCT01281202CompletedPhase 2/3Interventional

Vigabatrin for the Treatment of Cocaine Dependency

NCT01281202 is a phase 2/3 interventional trial sponsored by Catalyst Pharmaceuticals, Inc.. As of 21 Nov 2026, it is completed. It studies Matching Placebo and Vigabatrin in Cocaine Addiction and Cocaine Dependence. The registry lists an enrollment of 207 participants at 13 sites in 1 country. The registry lists a start date of 31 Jan 2011 and a primary completion date of 31 Oct 2012.

SponsorCatalyst Pharmaceuticals, Inc.Enrollment207Cocaine AddictionCocaine Dependence
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01281202
FieldValue
Registry IDNCT01281202
StatusCompleted
PhasePhase 2/3
Study typeInterventional trial
Lead sponsorCatalyst Pharmaceuticals, Inc.
Enrollment207
Registered sites13
Countries1
ConditionsCocaine Addiction and Cocaine Dependence
DrugsMatching Placebo and Vigabatrin
Start31 Jan 2011
Primary completion31 Oct 2012
Study completion31 Dec 2012
Last update posted18 May 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher than seen in subjects treated with placebo in addition to counseling.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States2 sites
  • Matrix Institute on Addictions

    Los Angeles

  • Friends Research Institute

    Torrance

Colorado, United States1 site
  • Va Medical Center

    Denver

Florida, United States1 site
  • University of Miami School of Medicine

    Miami

Illinois, United States1 site
  • Neuropsychiatric Research & Practice Assoc., Ltd.

    Oak Brook

Maryland, United States1 site
  • Mountain Manor Treatment Center @ Baltimore

    Baltimore

Massachusetts, United States1 site
  • Boston University School of Medicine

    Boston

New Mexico, United States1 site
  • Pacific Institute for Research and Evaluation

    Albuquerque

Pennsylvania, United States1 site
  • Western Psychiatric Inst. and Clinic

    Pittsburgh

South Carolina, United States1 site
  • Medical University of South Carolina

    Charleston

Texas, United States2 sites
  • Pillar Clinical Research, Llc

    Dallas

  • University of Texas Health Science Center at Houston

    Houston

Utah, United States1 site
  • George E Wahlen Va Medical Center

    Salt Lake City

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 1 siteIL1IndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCalifornia: 2 sitesCA2NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtah: 1 siteUT1Colorado: 1 siteCO1KansasKSArkansasARTennesseeTNNorth CarolinaNCSouth Carolina: 1 siteSC1New Mexico: 1 siteNM1OklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 2 sitesTX2Florida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Matching PlaceboVigabatrin →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01281202

Each answer restates registry values shown on this page.

What is NCT01281202?

NCT01281202 is a phase 2/3 interventional trial sponsored by Catalyst Pharmaceuticals, Inc.. It studies Matching Placebo and Vigabatrin in Cocaine Addiction and Cocaine Dependence.

Who leads NCT01281202?

The registry names Christopher J Stock, PharmD (study chair, George E. Wahlen VA Medical Center) and Kathleen Brady, MD, PhD (principal investigator, Medical University of South Carolina) as overall officials.

Where does NCT01281202 run?

The registry lists 13 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01281202 study?

The registered drug and biological interventions are Matching Placebo and Vigabatrin.

When did NCT01281202 end?

The registry lists a primary completion date of 31 Oct 2012 and a study completion date of 31 Dec 2012. The sponsor last updated the record on 18 May 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.